TABLE 1.
Epidemiological and microbiological characteristics of CTX-M-15-producing E. coli strains isolated from commercial swine, E. coli TOP10 (transformed) and E. coli TOP10
E. coli strain | Farm/stateb/yr | ST/phylogroup | MIC (μg/ml)c for: |
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AMP | CEF | CTX | CRO | EFT | CPD | CAZ | FEP | FOX | IPM | MER | CIP | ENO | NOR | GEN | AMI | TET | SUL | SXT | |||
180A | X/MG/2012 | 224/B1 | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 16 | 16 | 8 | ≤0.5 | ≤1 | ≥64 | ≥64 | ≥128 | ≥32 | 16 | ≥128 | ≥512 | ≥32 |
T-180A | ≥32 | ≥32 | 32 | 8 | 16 | ≥64 | 4 | 2 | ≤4 | ≤0.5 | ≤1 | 0.0035 | 0.007 | 0.06 | ≤4 | 2 | 4 | ≤12 | ≤2 | ||
180B | X/MG/2012 | 224/B1 | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 16 | 16 | 16 | ≤0.5 | ≤1 | ≥64 | ≥64 | ≥128 | ≥32 | 16 | ≥128 | ≥512 | ≥32 |
181 | X/MG/2012 | 224/B1 | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 16 | 8 | 8 | ≤0.5 | ≤1 | ≥64 | ≥64 | ≥128 | ≥32 | 16 | ≥128 | ≥512 | ≥32 |
T-181 | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 16 | 8 | 8 | ≤0.5 | ≤1 | 0.0035 | 0.007 | 0.12 | ≥32 | 2 | ≥128 | ≥512 | ≤2 | ||
187a | X/MG/2012 | 224/B1 | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 16 | 16 | 16 | ≤0.5 | ≤1 | ≥64 | ≥64 | ≥128 | ≥32 | 16 | ≥128 | ≥512 | ≥32 |
T-187a | ≥32 | ≥32 | ≥128 | 128 | ≥128 | ≥64 | 16 | 8 | ≤4 | ≤0.5 | ≤1 | 0.0035 | 0.0035 | 0.06 | ≥32 | 2 | 4 | ≥512 | ≤2 | ||
188 | X/MG/2012 | 224/B1 | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 16 | 16 | 16 | ≤0.5 | ≤1 | ≥64 | ≥64 | ≥128 | ≥32 | 8 | ≥128 | ≥512 | ≥32 |
T-188 | ≥32 | ≥32 | ≥128 | ≥256 | 128 | ≥64 | 16 | 16 | 8 | ≤0.5 | ≤1 | 0.0035 | 0.007 | 0.12 | ≥32 | 2 | 4 | ≥512 | ≤2 | ||
223Ba | Y/MG/2012 | 410/A | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 32 | 16 | 16 | ≤0.5 | ≤1 | ≥64 | ≥64 | ≥128 | ≤4 | 8 | ≥128 | ≥512 | ≥32 |
T-223Ba | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 32 | 16 | ≤4 | ≤0.5 | ≤1 | 0.0035 | 0.0035 | 0.12 | ≤4 | 8 | ≥128 | ≥512 | ≤2 | ||
468 | Z/PR/2012 | 1284/B1 | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 16 | 16 | 16 | ≤0.5 | ≤1 | ≥64 | ≥64 | ≥128 | ≥32 | 16 | ≥128 | ≥512 | ≥32 |
470 | Z/PR/2012 | 1284/B1 | ≥32 | ≥32 | ≥128 | ≥256 | ≥128 | ≥64 | 16 | ≥32 | 8 | ≤0.5 | ≤1 | ≥64 | ≥64 | ≥128 | ≥32 | 8 | ≥128 | ≥512 | ≥32 |
TOP10 | ≤8 | ≤8 | ≤0.2 | ≤1 | 0.5 | 1 | 0.5 | ≤1 | ≤4 | ≤0.5 | ≤1 | 0.0035 | 0.0035 | 0.06 | ≤4 | 2 | 4 | ≤12 | ≤2 |
Representative IncF-positive plasmids from E. coli ST224 and ST410 were selected for replicon sequence typing, obtaining the FAB allele formulas F-::A9::B1 and C1::A9::B1, respectively.
MG, Minas Gerais State; PR, Paraná State.
MICs were determined by microdilution technique using Sensititre ESBL-confirmatory MIC plates (TREK Diagnostic Systems, Thermo Fisher) or agar dilution methods; resistance is indicated in bold by using CLSI criteria (3, 4). AMP, ampicillin; CEF, cephalothin; CTX, cefotaxime; CRO, ceftriaxone; EFT, ceftiofur; CPD, cefpodoxime; CAZ, ceftazidima; FEP, cefepime; FOX, cefoxitin; IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; ENO, enrofloxacin; NOR, norfloxacin; GEN, gentamicin; AMI, amikacin; TET, tetracycline; SUL, sulfonamide; SXT, sulfamethoxazole-trimethoprim.